entertainment -WSS

entertainment

author：comprehensive 2025-09-29 23:04:10 - browse：662

Earlier this month, Intellia Therapeutics announced it was scrapping plans to include U.S.-based sites in one of its mid-stage CRISPR trials after the Food and Drug Administration requested additional data to support including female patients of childbearing potential. The move left many researchers wondering whether the specter of accidental germline transmission — which haunted early gene therapy trials — had now risen over the field of gene editing.

Over the weekend, Intellia sought to assure the gene editing community that no such thing is happening. At a meeting at Cold Spring Harbor Laboratory that drew more than 400 of the field’s top scientists, the company shared more detailed information about studies it has conducted to assess the risks that renegade CRISPR components could be getting into an egg or sperm. These studies demonstrate “that there’s no evidence of vertical germline transmission of those edits,” Jonathan Phillips, head of pharmacology and toxicology at Intellia, said during a presentation Saturday.

Intellia is one of the leading companies working to advance in vivo gene editing therapies. In a landmark study published in the New England Journal of Medicine in 2021, Intellia revealed data from six patients in its trial for a transthyretin amyloidosis therapy — showing for the first time that it was possible to precisely alter the DNA of particular cells within the human body to treat disease with a one-time infusion of CRISPR. Included in the supplementary material was a redacted version of the company’s package requesting authorization to start its clinical trial. It noted that during toxicology studies in non-human primates, Intellia scientists discovered that editing had taken place at low levels in organs other than the liver, including the spleen and adrenal glands. In three out of 12 female monkeys, they also found editing in the animals’ ovaries.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Physician executives need more than on

Wikipedia

WSS

Russia strikes Ukraine's critical port facilities in Odesa after halting grain deal

Trump got a 'target letter.' What is one and what does it mean?

Gilgo Beach murders: What questions remain following Rex Heuermann's arrest?

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Phenylephrine and the overlooked value of the placebo effect

Senate panel eyes new effort on drug shortages

explore

entertainment

focus

Peter Hotez and the public health issue of online harassment

Celebrate National Dole Whip Day for 3 days this week at Disney

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

3 questions for the future of Biden's cancer moonshot

Peter Hotez and the public health issue of online harassment

Stanford president to resign after investigation of research

Anesthesiologist group: stop taking Ozempic before surgery

Stroke deaths set to near 10 million globally by 2050

Malaria cases in Florida and Texas: Here’s what you need to know

A Q&A with the global head of Boehringer Ingelheim's innovation unit

hotspot

Researchers separate signal from noise in heart wearable data

The future of health care in the House

Sana to lay off nearly a third of staff, de

STAT's 2023 biotech VC rankings: ARCH Venture Partners tops list

Liquid biopsy for lung cancer is launched by Delfi

Readout Newsletter: Biotech news, including Moderna's Covid vaccine

leisure time

hotspot

Wikipedia

hotspot